Infections caused by biofilm-forming bacteria are a major threat to hospitalized patients and the main cause of chronic obstructive pulmonary disease and cystic fibrosis. There is an urgent necessity for novel therapeutic approaches, since current antibiotic delivery fails to eliminate biofilm-protected bacteria. In this study, ciprofloxacin-loaded poly(lactic-co-glycolic acid) nanoparticles, which were functionalized with DNase I, were fabricated using a green-solvent based method and their antibiofilm activity was assessed against Pseudomonas aeruginosa biofilms. Such nanoparticles constitute a paradigm shift in biofilm treatment, since, besides releasing ciprofloxacin in a controlled fashion, they are able to target and disassemble the biofilm by degrading the extracellular DNA that stabilize the biofilm matrix. These carriers were compared with free-soluble ciprofloxacin, and ciprofloxacin encapsulated in untreated and poly(lysine)-coated nanoparticles. DNase I-activated nanoparticles were not only able to prevent biofilm formation from planktonic bacteria, but they also successfully reduced established biofilm mass, size and living cell density, as observed in a dynamic environment in a flow cell biofilm assay. Moreover, repeated administration over three days of DNase I-coated nanoparticles encapsulating ciprofloxacin was able to reduce by 95% and then eradicate more than 99.8% of established biofilm, outperforming all the other nanoparticle formulations and the free-drug tested in this study. These promising results, together with minimal cytotoxicity as tested on J774 macrophages, allow obtaining novel antimicrobial nanoparticles, as well as provide clues to design the next generation of drug delivery devices to treat persistent bacterial infections.

The mycolic acids of several strains of Mycobacterium gordonae were examined by chromatographic and spectroscopic techniques. Both HPLC and TLC revealed two patterns of mycolates among the M. gordonae strains studied. As determined by TLC, one pattern was composed of α-, methoxy-and keto-mycolates ; the other was composed of these mycolates plus an additional component, which was identified as dicarboxy-mycolates. The dicarboxymycolates were only found in those M. gordonae strains that displayed a so-called HPLC-double-cluster pattern. Detailed structural analyses of the dicarboxy-mycolates indicated that these compounds contained predominantly 61-65 carbon atoms (C 63 was the major component) and a trans-1,2-disubstituted cyclopropane ring. Thus, the dicarboxy-mycolate content of strains of M. gordonae determines their HPLC pattern. In spite of the differences in their HPLC patterns, and although they belonged to different PCR-restriction length polymorphism clusters, all of the M. gordonae strains examined in this study were closely related on the basis of the structural features of their α-, keto-and methoxy-mycolates ; the predominant α-mycolates contained two cis-1,2-disubstituted cyclopropane rings, the major keto-mycolates contained a trans-1,2-disubstituted cyclopropane ring and the methoxy-mycolates contained one cis-or one trans-1,2-disubstituted cyclopropane ring. It is noteworthy that the strains containing dicarboxymycolates also displayed significant amounts of α-mycolates that contained one cis-1,2-disubstituted cyclopropane ring and one cis double bond. The results obtained in this study demonstrate heterogeneity among M. gordonae strains.